当地时间8月7日,礼来公布了一项口服减重药的重磅三期临床数据,患者用药72周后平均实现减重12.4%。同日,礼来公布第二季度业绩,上调全年利润预期。不过,由于此前市场对于这款口服减重药数据预期更高,礼来股价在盘前交易中下跌了约10%。礼来公布的最新临床数据显示,在超过3000名肥胖或至少伴有一种体重相关合并症的超重但无糖尿病的成人中,每日服用一次的GLP-1口服减重药Orforglipron,在...
Source Link当地时间8月7日,礼来公布了一项口服减重药的重磅三期临床数据,患者用药72周后平均实现减重12.4%。同日,礼来公布第二季度业绩,上调全年利润预期。不过,由于此前市场对于这款口服减重药数据预期更高,礼来股价在盘前交易中下跌了约10%。礼来公布的最新临床数据显示,在超过3000名肥胖或至少伴有一种体重相关合并症的超重但无糖尿病的成人中,每日服用一次的GLP-1口服减重药Orforglipron,在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.